Skip to content

Assessment of an Automated Optical Coherence Tomography and Camera : Reference Database

Assessment of an Automated Optical Coherence Tomography and Camera : Reference Database

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06511440
Enrollment
285
Registered
2024-07-22
Start date
2022-09-01
Completion date
2023-10-31
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The objective of this study is to establish the Reference database of Vision-700.

Detailed description

The objective is to collect and establish the Reference database of Vision-700, which is expected to recruit subjects with normal vision to collect the optical coherent tomography measurement data.

Interventions

OCT machines used for diagnostic purposes

Sponsors

Crystalvue Medical Coporation
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Subjects 22 years of age or older on the date of informed consent 2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Subjects presenting at the site with normal eyes bilaterally 4. IOP ≤ 21 mmHg bilaterally 5. BCVA 20/40 or better bilaterally

Exclusion criteria

1. Subjects unable to tolerate ophthalmic imaging. 2. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images. 3. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on manufacturer's recommendation), defined as fixation losses \> 20% or false positives \> 33%, or false negatives \> 33% 4. Visual field defects consistent with glaucomatous optic nerve damage based on at least one of the following two findings: On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; Glaucoma hemi-field test outside normal limits. 5. History of leukemia, dementia or multiple sclerosis. 6. History of hydroxychloroquine or chloroquine use. 7. Subjects with photosensitivity. 8. Subject having Photodynamic therapy (PDT) within 6 months. 9. Subjects taking photosensitivity drug currently.

Design outcomes

Primary

MeasureTime frameDescription
The reference OCT data2022/09/01The study is to collect OCT measurement data on normal healthy eyes in order to establish the reference data range for OCT parameters, included full retinal thickness (μm), retinal nerve fiber layer (μm), ganglion cell complex thickness (μm) and optic nerve head (μm). The reference data range will provide it with the doctor to dignoisis.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026